Bicara Therapeutics (BCAX) Income Statement (2023 - 2026)
Income Statement report data from Mar 31, 2023 to Mar 31, 2026 for Bicara Therapeutics (BCAX).
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Reported currency: USD
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Expenses | |||||||||||||
Research And Development | - | -92.10M | 33M (+33.06%) | 25M (-27.70%) | 34M (+72.36%) | 20M (+25.16%) | 16M (+0.63%) | 16M (+31.67%) | 12M (-49.37%) | 24M (+243.48%) | 6.90M | - | - |
Selling General And Administrative | 13M (+56.70%) | 8.13M (+5.58%) | 7.70M (+6.65%) | 7.22M (-3.22%) | 7.46M (+10.36%) | 6.76M (+42.02%) | 4.76M (+21.74%) | 3.91M (+17.07%) | 3.34M (-50.00%) | 6.68M (+157.92%) | 2.59M | - | - |
Operating Expenses | 60M (+46.50%) | 41M (+1.08%) | 41M (+27.05%) | 32M (-23.38%) | 42M (+56.87%) | 27M (+29.13%) | 21M (+4.46%) | 20M (+28.50%) | 15M (-49.37%) | 30M (+218.57%) | 9.53M | - | - |
Depreciation And Amortization | 40K (-55.56%) | 90K | - | - | 20K (-50.00%) | 40K | - | - | 10K (-50.00%) | 20K | - | - | - |
Operating Income | |||||||||||||
Operating Income | -60.24M (+46.50%) | -41.12M (+1.08%) | -40.68M (+27.05%) | -32.02M (-23.38%) | -41.79M (+56.87%) | -26.64M (+29.13%) | -20.63M (+4.46%) | -19.75M (+28.50%) | -15.37M (-49.37%) | -30.36M (+218.57%) | -9.53M | - | - |
Ebit | -60.24M (+46.50%) | -41.12M (+1.08%) | -40.68M (+27.05%) | -32.02M (-23.38%) | -41.79M (+56.87%) | -26.64M (+29.13%) | -20.63M (+4.46%) | -19.75M (+28.50%) | -15.37M (+12.52%) | -13.66M (+43.34%) | -9.53M (+2.58%) | -9.29M (+25.37%) | -7.41M |
EBITDA | -60.20M (+20.16%) | -50.10M (+38.05%) | -36.29M (+32.74%) | -27.34M (-34.55%) | -41.77M (+28.76%) | -32.44M (+85.58%) | -17.48M (+2.52%) | -17.05M (+11.00%) | -15.36M (+4700.00%) | -320.00K (-98.60%) | -22.84M (+145.86%) | -9.29M (+25.37%) | -7.41M |
Other Income / Expenses | |||||||||||||
Interest Income | 4.08M (+7.65%) | 3.79M (-13.67%) | 4.39M (-6.20%) | 4.68M (-6.59%) | 5.01M (-14.65%) | 5.87M (+86.35%) | 3.15M (+16.67%) | 2.70M (-5.92%) | 2.87M (+120.77%) | 1.30M (+12900.00%) | 10K | - | - |
Net Interest Income | 4.08M (+7.65%) | 3.79M (-13.67%) | 4.39M (-6.20%) | 4.68M (-6.59%) | 5.01M (-14.65%) | 5.87M (+86.35%) | 3.15M (+16.67%) | 2.70M (-5.92%) | 2.87M (+120.77%) | 1.30M (+12900.00%) | 10K | - | - |
Other Non Operating Income | 4.08M (-77.17%) | 18M (+307.06%) | 4.39M (-6.20%) | 4.68M (-6.59%) | 5.01M (-65.64%) | 15M (+362.86%) | 3.15M (+16.67%) | 2.70M (-5.92%) | 2.87M | -12.09M (-9.17%) | -13.31M | - | - |
Net Income | |||||||||||||
Income Before Tax | -56.16M (+50.44%) | -37.33M (+2.87%) | -36.29M (+32.74%) | -27.34M (-25.65%) | -36.77M (+77.03%) | -20.77M (+18.82%) | -17.48M (+2.52%) | -17.05M (+36.29%) | -12.51M (-57.05%) | -29.13M (+27.54%) | -22.84M | - | - |
Income Tax Expense | 50K (0.00%) | 50K (+25.00%) | 40K (-20.00%) | 50K (-28.57%) | 70K (-63.16%) | 190K | - | - | - | 10K | - | - | - |
Net Income From Continuing Operations | -56.21M (+50.33%) | -37.39M (+2.92%) | -36.33M (+32.64%) | -27.39M (-25.67%) | -36.85M (+75.81%) | -20.96M (+19.91%) | -17.48M (+2.52%) | -17.05M (+36.29%) | -12.51M (+0.56%) | -12.44M (-45.53%) | -22.84M (+145.86%) | -9.29M (+25.37%) | -7.41M |
Net Income | -56.21M (+50.33%) | -37.39M (+2.92%) | -36.33M (+32.64%) | -27.39M (-25.67%) | -36.85M (+75.81%) | -20.96M (+19.91%) | -17.48M (+2.52%) | -17.05M (+36.29%) | -12.51M (+0.56%) | -12.44M (-45.53%) | -22.84M (+145.86%) | -9.29M (+25.37%) | -7.41M |
Comprehensive Income Net Of Tax | -56.70M (-58.83%) | -137.71M (+277.60%) | -36.47M | - | -36.85M (-45.80%) | -67.99M (+288.96%) | -17.48M | - | - | - | - | - | - |